Warnock Charles A, Ondrusek Ashlin R, Edelman E Jennifer, Kershaw Trace, Muilenburg Jessica L
Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA.
Department of Social and Behavioral Sciences, Yale School of Public Health, New Haven, CT, USA.
Drug Alcohol Depend Rep. 2024 Mar 24;11:100228. doi: 10.1016/j.dadr.2024.100228. eCollection 2024 Jun.
Cannabis use is increasingly pervasive throughout the U.S. People in treatment for substance use disorders (SUD) may be especially at-risk of harm due to this changing context of cannabis in the U.S. This study's objective was to qualitatively describe experiences and beliefs around cannabis among people who had entered treatment for any SUD in the past 12-months.
From May to November of 2022, we conducted 27 semi-structured interviews (n=16 in Georgia, n=11 in Connecticut) with individuals in treatment for SUD in Georgia and Connecticut. Interviews were recorded, transcribed, and thematically analyzed using an emergent approach.
All participants had used cannabis in the past. Four themes emerged from the interviews. Participants: (1) perceived cannabis as an important contributor to non-cannabis substance use initiation in adolescence; (2) viewed cannabis as a substance with the potential to improve health with fewer side effects than prescription medications; (3) expressed conflicting opinions regarding cannabis as a trigger or tool to manage cravings for other non-cannabis substances currently; and 4) described concerns related to negative legal, social service, and treatment-related consequences as well as negative peer perception relating to the use of cannabis.
Although participants described cannabis's important role as an initiatory drug in adolescence and young adulthood, many felt that cannabis was a medicinal substance for a range of health challenges. These findings suggest SUD treatment clinicians should address medicinal beliefs related to cannabis among their clients and emphasizes the need for research on cannabis use and SUD treatment outcomes.
大麻在美国的使用越来越普遍。由于美国大麻环境的这种变化,接受物质使用障碍(SUD)治疗的人可能特别容易受到伤害。本研究的目的是定性描述在过去12个月内接受过任何SUD治疗的人群中,与大麻相关的经历和信念。
2022年5月至11月,我们对佐治亚州和康涅狄格州接受SUD治疗的个体进行了27次半结构化访谈(佐治亚州16人,康涅狄格州11人)。访谈进行了录音、转录,并采用一种新出现的方法进行了主题分析。
所有参与者过去都使用过大麻。访谈中出现了四个主题。参与者:(1)认为大麻是青少年非大麻物质使用开始的一个重要促成因素;(2)将大麻视为一种有可能改善健康且副作用比处方药少的物质;(3)对于大麻目前是引发对其他非大麻物质渴望的触发因素还是管理这种渴望的工具,表达了相互矛盾的观点;以及(4)描述了与大麻使用相关的负面法律、社会服务和治疗后果以及负面同伴看法的担忧。
尽管参与者描述了大麻在青少年和青年时期作为起始药物的重要作用,但许多人认为大麻是应对一系列健康挑战的药用物质。这些发现表明,SUD治疗临床医生应解决其客户中与大麻相关的药用信念问题,并强调对大麻使用和SUD治疗结果进行研究的必要性。